Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI: Randomized, Placebo-Controlled Phase II Clinical Trial in Patients with Latent Tuberculosis Infection: e89612

• Published in: PloS one Vol. 9; no. 2
• Main Authors: Nell, Andre S, D'lom, Eva, Bouic, Patrick, Sabate, Montserrat, Bosser, Ramon, Picas, Jordi, Amat, Merce, Churchyard, Gavin, Cardona, Pere-Joan
• Format: Journal Article
• Language: English
• Published: 01.02.2014
• Subjects: Human immunodeficiency virus; Mycobacterium

Objectives To evaluate the safety, tolerability and immunogenicity of three different doses (5, 25 and 50 mu g) of the novel antituberculous vaccine RUTI compared to placebo in subjects with latent tuberculosis infection. Methods and Findings Double-blind, randomized, placebo-controlled Phase II Cli...